Compositions and methods related to therapeutic cell systems for tumor growth inhibition
OwnerLenka Hoffman, Tom Wickham +3inventors
InventorsLenka Hoffman, Tom Wickham, Nathan Dowden, Torben Straight Nissen, Kristian Eric Teichert
Life of this patent
Estimating the term…
Abstract
The disclosure provides, e.g., enucleated erythroid cells comprising an amino acid degradative enzyme such as asparaginase and a targeting moiety such as an anti-CD33 antibody molecule. The cells may be used, e.g., to treat cancers such as AML.
Claims34
A genetically engineered, enucleated erythroid cell comprising:
- a first exogenous polypeptide comprising an amino acid degradative enzyme;
- and
- a second exogenous polypeptide comprising a cell targeting moiety.
3-6. (canceled)
8-16. (canceled)
18-20. (canceled)
22-31. (canceled)
(canceled)
(canceled)
(canceled)
43-45. (canceled)
47-53. (canceled)
(canceled)
(canceled)
60-65. (canceled)
(canceled)
A method of selecting a genetically engineered, enucleated erythroid cell for administration to a subject having a cancer, comprising:
- (i)
- (a) acquiring information about the sensitivity of a cancer to an amino acid degradative enzyme;
- (b) responsive to (a), selecting a genetically engineered, enucleated erythroid cell comprising an amino acid degradative enzyme to which the cancer is sensitive;
- and
- (c) administering the genetically engineered, enucleated erythroid cell comprising the amino acid degradative enzyme to the subject;
- (ii)
- (a) acquiring information about a cell surface marker of the cancer;
- (b) responsive to (a), selecting a genetically engineered, enucleated erythroid cell comprising a cell targeting moiety that binds the cell surface marker;
- and
- (c) administering the genetically engineered, enucleated erythroid cell comprising the cell targeting moiety to the subject;
- or
- (iii)
- (a) acquiring information about the sensitivity of a cancer to an amino acid degradative enzyme;
- (b) acquiring information about a cell surface marker of the cancer;
- (c) responsive to (a), selecting a genetically engineered, enucleated erythroid cell comprising an amino acid degradative enzyme to which the cancer is sensitive and further comprising a cell targeting moiety that binds the cell surface marker;
- and
- (d) administering the genetically engineered, enucleated erythroid cell comprising the amino acid degradative enzyme and the cell targeting moiety to the subject.
69-70. (canceled)
Dependencies are inferred from the claim text.